Peptide Tolerance & Cycling: Why Peptides Stop Working

What Is Peptide Tolerance?

Tolerance refers to a diminished biological response to a substance after repeated exposure. In the context of peptides, this primarily occurs through receptor desensitisation — the target receptors become less responsive to stimulation over time, requiring higher doses to achieve the same effect.

This is distinct from tachyphylaxis, which is a more rapid loss of response (sometimes after just a few doses) due to receptor internalisation or depletion of downstream signalling molecules. Both phenomena are relevant to peptide use but occur through different mechanisms and timescales.

Not all peptides develop tolerance equally. Growth hormone secretagogues (particularly GHRP-6 and Hexarelin) are well-documented to show significant desensitisation within weeks, while BPC-157 appears to maintain effectiveness throughout typical protocol durations. Understanding which peptides are prone to tolerance — and which are not — is essential for designing effective protocols.

Mechanisms of Receptor Desensitisation

Homologous desensitisation occurs when repeated activation of a specific receptor leads to its phosphorylation by G protein-coupled receptor kinases (GRKs), followed by beta-arrestin binding and receptor internalisation. The receptor is physically removed from the cell surface, reducing the cell's ability to respond to the peptide ligand.

Heterologous desensitisation involves cross-talk between signalling pathways — activation of one receptor pathway can reduce sensitivity of a different receptor type. This is relevant when using multiple peptides simultaneously, as stimulation of one pathway may inadvertently dampen another.

Downstream depletion occurs when the intracellular signalling molecules needed to transduce the receptor signal become exhausted. For GH secretagogues, this can mean depletion of pituitary GH stores, reducing the amount of growth hormone available for release even when the receptor is adequately stimulated.

Which Peptides Develop Tolerance?

Cycling Protocols: The Evidence

Cycling — alternating periods of use (on-cycle) with breaks (off-cycle) — is the primary strategy for managing tolerance. The rationale is that receptor populations recover during the off period, restoring sensitivity for the next on-cycle.

Common cycling patterns for GH secretagogues:

• 5 days on / 2 days off: The most commonly cited pattern. Weekday dosing with weekend breaks may help maintain pituitary GH stores. Limited formal evidence but widely adopted.
• 4 weeks on / 2 weeks off: A longer cycle that allows more complete receptor recovery. More relevant for peptides with stronger desensitisation profiles like GHRP-6.
• 3 months on / 1 month off: Used for some anti-ageing protocols (Epitalon, CJC-1295). Allows assessment of sustained benefits and provides a washout period.

For GLP-1 agonists (semaglutide, tirzepatide), cycling is NOT recommended. These medications work through sustained receptor activation with dose titration managing adaptation. Stopping and restarting can cause rebound appetite and weight regain.

Practical Implications for UK Users

Understanding tolerance has direct practical implications. If you notice diminishing effects from a GH secretagogue, the evidence suggests taking a break rather than increasing the dose — dose escalation accelerates tolerance and increases side effects without proportionally increasing benefits.

Monitoring through blood work (IGF-1 for GH peptides, HbA1c for metabolic peptides) provides objective data on whether a peptide is still producing its intended biological effect, removing guesswork about perceived tolerance versus other factors.